April 17, 2014 / 7:20 PM / 4 years ago

Teva willing to post $500 million bond in Copaxone case

WASHINGTON, April 17 (Reuters) - Teva Pharmaceutical Industries Ltd on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

Teva already had asked the court for a stay of the July 2013 ruling by the U.S. Court of Appeals for the Federal Circuit that invalidated some of its patents for the top-selling multiple sclerosis drug, Copaxone. The case was won by two teams developing generic versions of the drug: one involving Novartis AG’s Sandoz Inc and Momenta Pharmaceuticals Inc, and the other involving Mylan In c and Natco Pharma Ltd.

The Supreme Court has yet to respond to Teva’s application. (Reporting by Lawrence Hurley; Editing by Howard Goller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below